Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052897 · ClinicalTrials.gov registry record · Phase 1
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
A Phase 1 study of Anal Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00052897 is a Phase 1 study of Anal Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00052897, a Phase 1 study of Anal Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia. Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in preventing anal cancer.
Conditions Studied
Interventions
- BIOLOGICAL HspE7
Study Locations (1)
California
- UCSF Comprehensive Cancer Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2002-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00052897
The ClinicalTrials.gov registry entry for NCT00052897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 1 intervention - of which HspE7 is the first listed.
NCT00052897 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00052897 about?
NCT00052897 is a clinical study titled "SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia". Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia. Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in preventing anal cancer.
What is the current status of trial NCT00052897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2002-12.
What conditions does trial NCT00052897 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT00052897?
The interventions under investigation include: HspE7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00052897?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00052897 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
-
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.